Indianapolis: Eli Lilly and Company and Scorpion Therapeutics, Inc., a private biotechnology company developing small ...

While Funksec clearly positions itself as a ransomware-as-a-service operation, it’s also somewhat of a hacktivist group. The ...

After selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the ...

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

January 10, 2025, marks the second anniversary of the death of Tyre Nichols, a 29-year-old Black man who was restrained and ...

The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors.

The Wall Street giant's new group will capitalize on a private-credit surge and anticipated private-equity deal boom. The company makes an explicit appeal to the president-elect to reject tighter ...

Eli Lilly said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to ...

Lilly will acquire Scorpion's experimental oral therapy, STX-478, which is currently being tested in early-stage trials for ...

Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash.

Developed with the help of AI, the emerging FunkSec ransomware claimed over 80 victims in December 2024. An emerging ransomware group named FunkSec has risen to fame after claiming responsibility for ...